fluoxymesterone

17α-alkylated androgen · Androgen; Performance enhancing drug (illicitly); Hepatotoxicity inducer (adverse effect); HDL-C lowering agent (adverse effect); LDL-C increasing agent (adverse effect); Virilization inducer (adverse effect); Facial hirsutism inducer (adverse effect); Body hirsutism inducer (adverse effect); Temporal hair recession inducer (adverse effect); Acne inducer (adverse effect); Phallic enlargement inducer (adverse effect); Clitoral enlargement inducer (adverse effect); Premature epiphyseal closure inducer (adverse effect); Stunting of linear growth inducer (adverse effect); Estrogen formation non-blocker (if aromatizable); Gynecomastia inducer (if aromatizable); Testicular function suppressor (in high doses); Spermatogenesis suppressor (in high doses); Fertility reduction agent (in high doses); Erythrocytosis inducer (in high doses); Salt and water retention inducer (in high doses); Peripheral edema inducer (in high doses); Male pattern baldness inducer (in adulthood); Benign prostatic hyperplasia inducer (in adulthood); Prostate cancer promoter (in adulthood, if existing); Epiphyseal closure accelerator (in puberty); Growth spurt inducer (in puberty); Long bone growth cessation agent (in puberty); Laryngeal thickening agent (in puberty); Voice lowering agent (in puberty); Hair coarsening agent (in puberty); Skin oiliness inducer (in puberty); Acne inducer (in puberty); Libido inducer (in puberty); Energy enhancer (in adults with low levels); Hemoglobin normalizer (in adults with low levels); Muscle mass improver (in adults with low levels); Fat mass decreaser (in adults with low levels); Bone density increaser (in adults with low levels); Trabecular connectivity increaser (in adults with low levels); Phallic enlargement agent (in puberty); Scrotal rugation agent (in puberty); Prostate secretion inducer (in puberty); Androgenic effect inducer (in certain tissues, via AR); Estrogenic effect inducer (in certain tissues, via conversion to estradiol); Dihydrotestosterone effect inducer (in certain tissues, via conversion to dihydrotestosterone); Wolffian duct differentiation agent (in fetal development); External genitalia masculinization agent (in fetal development); Phallic growth agent (in late gestation); Skeletal muscle mass and strength enhancer; Erythropoiesis enhancer; Bone growth enhancer; Libido enhancer; Epiphyseal closure enhancer; Bone density enhancer; Hair follicle growth enhancer (in puberty); Sexual hair development agent (in puberty); Adrenal androgen action blocker (when used with GnRH analogues for prostate cancer); Glucocorticoid excess treatment (ketoconazole specific use, not testosterone); Hirsutism treatment (flutamide specific use, spironolactone specific use, cyproterone acetate specific use, finasteride specific use); Lower urinary tract symptoms treatment (finasteride specific use, dutasteride specific use); Benign prostatic hyperplasia treatment (finasteride specific use, dutasteride specific use); Male pattern baldness treatment (finasteride specific use); Erectile dysfunction treatment (PDE5 inhibitors specific use); Pulmonary arterial hypertension treatment (PDE5 inhibitors specific use); Anemia treatment (danazol, methyltestosterone specific uses); Idiopathic thrombocytopenic purpura treatment (danazol specific use); Angioedema treatment (danazol, oxandrolone specific uses); Endometriosis treatment (danazol, leuprolide, goserelin specific uses); Fibrocystic breast disease treatment (danazol specific use); Uterine leiomyomata treatment (leuprolide specific use); Precocious puberty treatment (leuprolide, histrelin specific uses); Breast cancer treatment (goserelin specific use); Dysfunctional uterine bleeding treatment (goserelin specific use); Fluid retention treatment (spironolactone specific use); Hypertension treatment (spironolactone specific use); Metabolic parameter improver (not shown for testosterone, but mentioned as not improved in senescence studies)